Head-to-head evidence
Allo-RevCAR01-T vs CD123 targeted CAR-NK cells
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
Allo-RevCAR01-T
Developed by AvenCell Europe GmbH
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT05949125 (registry estimate)
CD123 targeted CAR-NK cells
Developed by Chongqing Precision Biotech Co., Ltd
NCT06006403 · Phase 1/2 · completed
This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Allo-RevCAR01-T's landscape · CD123 targeted CAR-NK cells's landscape